Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of
the study to determine and evaluate the safety and tolerability of repeated treatments with a
genetically engineered herpes simplex virus NV1020 administered locoregionally to the liver.
Stage 2 is to evaluate the dose found in Stage 1 to be "optimally tolerated". Stage 2 is to
assess the efficacy of the optimally tolerated dose of NV1020 by itself and in combination
with second-line chemotherapy.
Assignment to Stage 1 or Stage 2 of the study is determined by when the patient enters the
study.